Apogee Acquisition Corp
Government Contracts & Awards
No recent government contracts or awards found.
Proprietary Tech & Patents
No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
AbbVie Anticipates Apogee Acquisition To Negatively Impact Adj Diluted EPS By $0.14 This Year, $0.46 In 2027, Accretion Beginning In 2032
AbbVie (NYSE:ABBV) today announced that it expects its acquisition of Apogee to negatively impact adjusted diluted earnings per share (EPS) by $0.14 in 2026 (partial year) and approximately $0.46 in 2027, with accretion
H.C. Wainwright Keeps Buy Rating on Oruka (ORKA) After Apogee Acquisition News
Oruka Therapeutics, Inc. (NASDAQ:ORKA) is one of the Top 10 Hot Stocks with the Highest Upside Potential. On June 23, H.C. Wainwright reaffirmed its Buy rating on Oruka Therapeutics, Inc. (NASDAQ:ORKA) with a price target of $120 on the stock. This update comes after AbbVie announced that it is acquiring Apogee Therapeutics. AbbVie said that […]
AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst
AbbVie will acquire Apogee Therapeutics for $10.9 billion, with analyst citing long-term immunology growth despite near-term dilution.
Congressional Trades in $AACP
No disclosed congressional trades found in $AACP.
Insider Trades (Form 4)
APOGEE ACQUISITION SPONSOR LLC
Watson Thomas Lloyd
Key People
Watson Thomas Lloyd
Chief Operating Officer
Political Giving
No disclosed PAC contributions found for this entity.
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro